Indicated for: chronic myeloid leukemia; gastrointestinal stromal tumors
Route of administration: oral
Substance: imatinib (tyrosine kinase inhibitor)
ATC: L01EA01 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors)
Imatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and other cancers, such as gastrointestinal stromal tumors (GIST). It works by blocking the activity of abnormal proteins that drive cancer cell growth.
The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the recommended dose to maximize treatment effectiveness.
Side effects may include nausea, vomiting, fluid retention, muscle pain, or fatigue. In rare cases, severe allergic reactions or liver failure may occur.
Imatinib is not recommended for patients with hypersensitivity to this medication or severe liver impairment.